Oncolytic viruses deliver B7H3-targeting BiTE to the tumor site, enhancing antitumor T-cell immunity
Dec. 17, 2024
B7H3 is a pan-cancer antigen considered a promising target for immunotherapy. However, targeting B7H3 using bispecific T-cell engagers (BiTEs) presents the problem of systemic toxicity.